The Search for New Drugs: Part II

The transcript discusses Pfizer's approach to R&D spending, focusing on improving productivity by selecting specific therapeutic areas and restructuring research and development processes. It highlights the importance of balancing internal and external investments, reducing failure rates, and utilizing AI and data in clinical trials. The discussion also touches on the challenges of drug development, particularly in areas like Alzheimer's, and the need for regulatory and patent system adaptations.

How does Pfizer balance between in-house development and acquiring drugs from external sources?

What factors contribute to the high failure rate in pharmaceutical development, according to the discussion?

How does Pfizer's approach to external partnerships influence their research and development strategy?

What are the implications of the regulatory system on the development of treatments for diseases like Alzheimer's?